Aeglea BioTherapeutics Statistics Share Statistics Aeglea BioTherapeutics has 4.05M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 4.05M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) n/a Shares Floating 1.92M Failed to Deliver (FTD) Shares 100 FTD / Avg. Volume 0.17%
Short Selling Information The latest short interest is 139.69K, so 3.45% of the outstanding
shares have been sold short.
Short Interest 139.69K Short % of Shares Out 3.45% Short % of Float 3.47% Short Ratio (days to cover) 4.58
Valuation Ratios The PE ratio is -34.74 and the forward
PE ratio is null.
Aeglea BioTherapeutics's PEG ratio is
0.
PE Ratio -34.74 Forward PE n/a PS Ratio 0 Forward PS n/a PB Ratio 13.95 P/FCF Ratio -45.9 PEG Ratio 0
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Aeglea BioTherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 11.26,
with a Debt / Equity ratio of 0.
Current Ratio 11.26 Quick Ratio 11.26 Debt / Equity 0 Debt / EBITDA n/a Debt / FCF n/a Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-3.01M Employee Count 69 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -51K Effective Tax Rate 0.02%
Stock Price Statistics The stock price has increased by -37.77% in the
last 52 weeks. The beta is 2.57, so Aeglea BioTherapeutics's
price volatility has been higher than the market average.
Beta 2.57 52-Week Price Change -37.77% 50-Day Moving Average 13.75 200-Day Moving Average 10.26 Relative Strength Index (RSI) 64.73 Average Volume (20 Days) 59,537
Income Statement
Revenue n/a Gross Profit n/a Operating Income -208.57M Net Income -208.02M EBITDA -208.57M EBIT n/a Earnings Per Share (EPS) -0.56
Full Income Statement Balance Sheet The company has 89.42M in cash and 0 in
debt, giving a net cash position of 89.42M.
Cash & Cash Equivalents 89.42M Total Debt n/a Net Cash n/a Retained Earnings -972.43M Total Assets 569.78M Working Capital 499.09M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -157.41M
and capital expenditures 0, giving a free cash flow of -157.41M.
Operating Cash Flow -157.41M Capital Expenditures n/a Free Cash Flow -157.41M FCF Per Share -0.42
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
Dividends & Yields AGLE does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast Currently there are no analyst rating for AGLE.
Price Target n/a Price Target Difference n/a Analyst Consensus n/a Analyst Count n/a
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 8, 2023. It was a
backward
split with a ratio of 1:25.
Last Split Date Sep 8, 2023 Split Type backward Split Ratio 1:25
Scores Altman Z-Score -1.61 Piotroski F-Score 1
